NCT04891991View on ClinicalTrials.gov

Intravitreal Infliximab for Proliferative Vitreoretinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 26, 2021

Primary Completion Date

November 10, 2023

Study Completion Date

November 10, 2023

Conditions
Rhegmatogenous Retinal DetachmentProliferative VitreoretinopathyRetinal Detachment
Interventions
DRUG

Intravitreal infliximab

1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.

PROCEDURE

Pars plana vitrectomy

Standard pars plana vitrectomy

Trial Locations (1)

11956

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy | Biotech Hunter | Biotech Hunter